文献速递淋巴瘤造血干细胞移植与细胞治疗

复发儿童间变性大细胞淋巴瘤的干细胞移植与长春花碱单药治疗:国际前瞻性ALCL-Relapse试验结果

Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
PubMed 文献 · J Clin Oncol · 2020-07-30

该国际前瞻性ALCL-Relapse试验按复发时间和CD3表达对复发儿童间变性大细胞淋巴瘤进行风险分层治疗。105例可评估患者5年无事件生存率为53%±5%,5年总生存率为78%±4%。结论认为复发时间短是后续复发最强预测因素,异基因干细胞移植为高危复发患者提供治愈机会,长春花碱单药对晚期复发有效但对早期复发无效。

要点

  • 105例可评估患者5年无事件生存率为53%±5%,5年总生存率为78%±4%。
  • 极高危组5年无事件生存率41%±12%,高危组62%±10%,中危组44%±9%,低危组81%±9%。
  • 中危组按方案行自体干细胞移植的23例患者5年无事件生存率为30%±10%,总生存率为78%±9%。

核心结论

  • 复发时间短是后续复发的最强预测因素。
  • 异基因干细胞移植为高危复发间变性大细胞淋巴瘤患者提供治愈机会。
  • 早期复发患者接受自体干细胞移植无效。
  • 长春花碱单药对晚期复发患者可实现治愈,但对早期复发无效。

研究设计与样本

  • 国际前瞻性ALCL-Relapse试验(ClinicalTrials.gov标识NCT00317408),按复发时间和CD3表达进行风险分层治疗。
  • 116例患者符合纳入标准,105例无中枢神经系统受累的可评估患者纳入分析。
  • 极高危(前线治疗期间进展)或高危(CD3阳性复发)患者于再诱导化疗后接受异基因干细胞移植。
  • 中危(初诊后1年内CD3阴性复发或既往暴露于长春花碱)患者接受卡莫司汀-依托泊苷-阿糖胞苷-美法仑后自体干细胞移植;该组提前终止,后续患者改为长春花碱单药治疗。
  • 低危(初诊后超过1年CD3阴性复发)患者接受长春花碱单药治疗。

主要发现

  • 105例可评估患者5年无事件生存率为53%±5%,5年总生存率为78%±4%。
  • 自体干细胞移植终止前,极高危组(n=17)、高危组(n=26)、中危组(n=32)和低危组(n=21)的无事件生存率分别为41%±12%、62%±10%、44%±9%和81%±9%。
  • 上述四组的总生存率分别为59%±12%、73%±9%、78%±7%和90%±6%。
  • 仅分析中危组中按方案以自体干细胞移植巩固的23例患者,无事件生存率和总生存率分别为30%±10%和78%±9%。
  • 修正案后接受长春花碱单药治疗的全部5例中危患者均再次复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the efficacy of a risk-stratified treatment of children with relapsed anaplastic large cell lymphoma (ALCL). The ALCL-Relapse trial (ClinicalTrials.gov identifier: NCT00317408) stratified patients according to the time of relapse and CD3 expression to prospectively test reinduction approaches combined with consolidation by allogeneic or autologous hematopoietic stem cell transplantation (SCT) and vinblastine monotherapy. PATIENTS AND METHODS: Patients with progression during frontline therapy (very high risk) or a CD3-positive relapse (high risk) were scheduled for allogeneic SCT after reinduction chemotherapy. Patients with a CD3-negative relapse within 1 year after initial diagnosis or prior exposure to vinblastine (intermediate risk) received autologous SCT after carmustine-etoposide-cytarabine-melphalan. This arm was terminated prematurely, and subsequent patients received vinblastine monotherapy instead. Patients with a CD3-negative relapse > 1 year after initial diagnosis (low risk) received vinblastine monotherapy. RESULTS: One hundred sixteen patients met the inclusion criteria; 105 evaluable patients with CNS-negative disease had a 5-year event-free survival (EFS) of 53% ± 5% and a 5-year overall survival (OS) of 78% ± 4%. Before termination of autologous SCT, EFS rates of patients in the very-high- (n = 17), high- (n = 26), intermediate- (n = 32), and low- (n = 21) risk groups were 41% ± 12%, 62% ± 10%, 44% ± 9%, and 81% ± 9%; the respective OS rates were 59% ± 12%, 73% ± 9%, 78% ± 7%, and 90% ± 6%. Analyzing only the patients in the intermediate-risk group consolidated per protocol by autologous SCT, EFS and OS of 23 patients were 30% ± 10% and 78% ± 9%, respectively. All 5 patients with intermediate risk receiving vinblastine monotherapy after the amendment experienced relapse again. CONCLUSION: Shorter time to relapse was the strongest predictor of subsequent relapse. Allogeneic SCT offers a chance for cure in patients with high-risk ALCL relapse. For early relapsed ALCL autologous SCT was not effective. Vinblastine monotherapy achieved cure in patients with late relapse; however, it was not effective for early relapses.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Knörr F, Brugières L, Pillon M, et al. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. 2020. PMID: 32730187. doi:10.1200/JCO.20.00157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。